Actively Recruiting
Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution
Led by First Affiliated Hospital of Zhejiang University · Updated on 2025-08-06
1500
Participants Needed
1
Research Sites
136 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The intricate interplay between systemic immunity and tumors profoundly influences not only the onset and progression of tumors but also serves as a crucial window into understanding tumor evolution and treatment status. This project aims to establish a large, multi-center pancreatic cancer cohort and a standardized clinical sample repository, capturing multimodal immunity big data on pancreatic cancer occurrence, progression, and treatment response across the spatial dimension of "peripheral versus local" and the temporal dimension of "tumor evolution/pre- and post-treatment." By integrating patient imaging and clinical information, the investigators will develop a technical platform for intelligent extraction and fusion analysis of cross-scale, multimodal data, thereby mapping the immunity landscape of pancreatic cancer evolution, identifying characteristic changes in immunity parameters, and devising an AI model for early pancreatic cancer diagnosis with high accuracy and robust generalization capabilities, while also exploring the model's interpretability. Additionally, the investigators will focus on specific immune cell subsets associated with pancreatic cancer evolution and treatment response, elucidating their roles and mechanisms in the occurrence, development, and drug resistance of pancreatic cancer. This project will establish a high-quality, standardized, and shareable pancreatic cancer immunity sample and data repository, refine the framework for multi-dimensional immunity data fusion and analysis, and create a time-space atlas of local and systemic immunity in pancreatic cancer. This will facilitate a deeper understanding of the dynamics of systemic and local immunity in early-stage pancreatic cancer and at various stages of its evolution, offering novel insights and approaches for the diagnosis and treatment of pancreatic cancer.
CONDITIONS
Official Title
Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy individuals without benign or malignant liver, gallbladder, and pancreas diseases
- Primary pancreatic ductal adenocarcinoma (PDAC)
- Patients with benign pancreatic tumors
- Patients with intraductal papillary mucinous neoplasm (IPMN) diagnosed by pathology or imaging
You will not qualify if you...
- Having autoimmune diseases
- Accompanied by other malignant tumors
- History of tumor treatment except cured thyroid or breast cancer for more than 5 years
- Acute infection
- History of blood transfusion within the past 6 months or use of drugs affecting blood components within 2 weeks
- Organ decompensation dysfunction
- Immunodeficiency syndrome
- Hematological precancerous lesions
- Receiving immunosuppressive therapy
- Diagnosed coagulation disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the First Affliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310003
Actively Recruiting
Research Team
Y
Yangyang Wang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here